Automated and Closed Cell Therapy Processing Systems Market Report 2025

The automated and closed cell therapy processing systems market size has grown rapidly in recent years. It will grow from $1.31 billion in 2024 to $1.53 billion in 2025 at a compound annual growth rate (CAGR) of 17.2%. The growth in the historic period can be attributed to rising demand for personalized medicine, an expanding pipeline of cell and gene therapies, increasing clinical trials for cell-based treatments, the growth of biopharmaceutical manufacturing capabilities, and heightened investment in regenerative medicine.

The automated and closed cell therapy processing systems market size is expected to see rapid growth in the next few years. It will grow to $2.86 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to the increasing adoption of automation in cell therapy manufacturing, rising regulatory support for advanced therapy medicinal products, growing need for scalable and reproducible processes, expanding applications of cell therapies beyond oncology, and higher demand for cost-effective manufacturing solutions. Major trends in the forecast period include technological advancements in automated cell processing platforms, innovations in closed-system bioreactors, integration of artificial intelligence, development of modular manufacturing systems, and a growing focus on end-to-end process automation.

The rising demand for personalized medicine is expected to drive the growth of the automated and closed cell therapy processing systems market in the coming years. Personalized medicine tailors treatments and healthcare decisions to an individual’s unique genetic, molecular, and clinical profile. This approach is increasingly sought after as patients look for therapies that improve efficacy, minimize side effects, and align with their specific biological makeup. Automated and closed-cell therapy processing systems facilitate personalized medicine by enabling precise, sterile, and consistent production of patient-specific therapies with minimal manual handling and reduced contamination risk. For example, according to the Personalized Medicine Coalition, a US-based healthcare organization, in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from six approvals in 2022. As a result, the growing adoption of personalized medicine is propelling the growth of the automated and closed-cell therapy processing systems market.

Leading companies in this market are focusing on technological innovations, such as advanced cell preparation platforms, to enhance efficiency and maintain quality in cell therapy manufacturing. These platforms are automated systems designed to isolate, process, and prepare cells efficiently for clinical use or further analysis while reducing manual labor and contamination risks. In October 2024, Sino-Biocan Biotechnology Ltd., a China-based biotech company, launched the WUKONG Automated, Closed, Integrated Cell Processing System. This fully automated, closed platform streamlines the entire workflow from blood collection to cell culture and final filling. It is intended for hospitals, pharmaceutical R&D teams, and contract development and manufacturing organizations, offering improved efficiency, reduced contamination risks, and GMP-grade consistency through intelligent controls and real-time monitoring.

In March 2024, Donaldson Company Inc., a US-based filtration company, acquired Univercells Technologies for $157.28 million (€136 million). This acquisition strengthens Donaldson’s capabilities in life sciences by integrating Univercells Technologies’ automated and closed biomanufacturing platforms to provide end-to-end solutions for cell and gene therapy production. Univercells Technologies is a Belgium-based provider of automated and closed cell therapy processing systems.

Major players in the automated and closed cell therapy processing systems market are Thermo Fisher Scientific Inc., Fresenius SE & Co. KGaA, Danaher Corporation, Merck KGaA, Parker Hannifin Corp., Corning Incorporated, Kawasaki Heavy Industries Ltd., Dover Corporation, Lonza Group AG, Terumo Corporation, Sartorius AG, Charles River Laboratories International Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Hamilton Company, Repligen Corporation, Cellares Inc., Ori Biotech Ltd., and Autolus Therapeutics Plc.

North America was the largest region in the automated and closed cell therapy processing systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in automated and closed cell therapy processing systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the automated and closed cell therapy processing systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Automated and closed cell therapy processing systems are integrated platforms designed to carry out multiple steps of cell therapy manufacturing within a sealed, controlled environment. These systems minimize manual handling, reducing contamination risks and ensuring the production of consistent, high-quality cell products. By automating processes such as cell isolation, expansion, and formulation, they enhance efficiency, reproducibility, and compliance with stringent regulatory standards.

The primary components of automated and closed cell therapy processing systems include software, hardware, and consumables. The software consists of specialized programs that control, monitor, and manage the sterile and precise manufacturing of cell-based therapies. These systems leverage technologies such as microfluidics, robotics, bioreactors, single-use technology, and three-dimensional (3D) cell culture. Key workflows include cryopreservation, separation, fill-finish, expansion, apheresis, and more. They are applied across fields such as oncology, regenerative medicine, autoimmune diseases, infectious diseases, and cardiovascular diseases, serving end users including pharmaceutical and biotechnology companies, research institutes, contract manufacturing organizations, and hospitals.

The automated and closed cell therapy processing systems market research report is one of a series of new reports that provides automated and closed cell therapy processing systems market statistics, including the automated and closed cell therapy processing systems industry global market size, regional shares, competitors with the automated and closed cell therapy processing systems market share, detailed automated and closed cell therapy processing systems market segments, market trends, and opportunities, and any further data you may need to thrive in the automated and closed cell therapy processing systems industry. This automated and closed cell therapy processing systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The automated and closed cell therapy processing systems market includes revenues earned by entities by providing services such as cell separation and isolation, quality control integration, genetic modification, and cell activation. The market value includes the value of related goods sold by the service provider or included within the service offering. The automated and closed cell therapy processing systems market also includes sales of control systems, single-use consumables, automated cell washing systems, and closed-system fluid handling components. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.